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Summary
Background The eﬀ ectiveness of intermittent montelukast for wheeze in young children is unclear. We aimed to 
assess whether intermittent montelukast is better than placebo for treatment of wheeze in this age group. Because 
copy numbers of the Sp1-binding motif in the arachidonate 5-lipoxygenase (ALOX5) gene promoter (either 5/5, 5/x, 
or x/x, where x does not equal 5) modiﬁ es response to montelukast in adults, we stratiﬁ ed by this genotype.
Methods We did this multicentre, parallel-group, randomised, placebo-controlled trial between Oct 1, 2010, and Dec 20, 
2013, at 21 primary care sites and 41 secondary care sites in England and Scotland. Children aged 10 months to 5 years 
with two or more wheeze episodes were allocated to either a 5/5 or 5/x+x/x ALOX5 promoter genotype stratum, then 
randomly assigned (1:1) via a permuted block schedule (size ten), to receive intermittent montelukast or placebo given 
by parents at each wheeze episode over a 12 month period. Clinical investigators and parents were masked to treatment 
group and genotype strata. The primary outcome was number of unscheduled medical attendances for wheezing 
episodes. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01142505.
Findings We randomly assigned 1358 children to receive montelukast (n=669) or placebo (n=677). Consent was 
withdrawn for 12 (1%) children. Primary outcome data were available for 1308 (96%) children. There was no diﬀ erence 
in unscheduled medical attendances for wheezing episodes between children in the montelukast and placebo groups 
(mean 2·0 [SD 2·6] vs 2·3 [2·7]; incidence rate ratio [IRR] 0·88, 95% CI: 0·77–1·01; p=0·06). Compared with placebo, 
unscheduled medical attendances for wheezing episodes were reduced in children given montelukast in the 5/5 
stratum (2·0 [2·7] vs 2·4 [3·0]; IRR 0·80, 95% CI 0·68–0·95; p=0·01), but not in those in the 5/x+x/x stratum 
(2·0 [2·5] vs 2·0 [2·3]; 1·03, 0·83–1·29; p=0·79, pinteraction=0·08). We recorded one serious adverse event, which was a 
skin reaction in a child allocated to placebo.
Interpretation Our ﬁ ndings show no clear beneﬁ t of intermittent montelukast in young children with wheeze. 
However, the 5/5 ALOX5 promoter genotype might identify a montelukast-responsive subgroup.
Funding Medical Research Council (UK) and National Institute for Health Research.
Copyright © Nwokoro et al. Open Access article distributed under the terms of CC BY.
Introduction
Wheeze in children aged 10 months to 5 years is 
characterised by recurrent episodes that are frequently 
triggered by viral colds.1 Episodes of wheeze in young 
children might be clinically severe and can result in 
parents seeking medical attention.2 Indeed, an audit of 
UK paediatric hospital admissions for acute wheeze from 
1998 to 2005 showed that most admissions were of 
children younger than 5 years.3 Because wheeze in young 
children is characterised by long asymptomatic periods 
interspersed with short intense episodes,1 intermittent 
treatment strategies have been assessed. We previously 
reported that a short course of oral corticosteroids initiated 
by parents at the onset of a wheeze episode is not eﬀ ective 
for reducing the severity of wheeze in children aged 
1–5 years.4 By contrast, intermittent high-dose inhaled 
corticosteroids reduce the risk of clinically severe wheeze 
episodes by 30% in that age group.5 However, this strategy 
is associated with clinically relevant growth suppression.5 
Because montelukast (a cysteinyl leukotriene receptor 
blocker) does not suppress growth,6 the eﬀ ectiveness of 
intermittent montelukast for wheeze in young children is 
of clinical interest.
To date, trials of intermittent montelukast have 
reported conﬂ icting results: ﬁ ndings from a subgroup 
analysis in Robertson and colleagues’ trial7 of children 
aged 2–14 years showed that intermittent montelukast 
given over 12 months reduced unscheduled use of acute 
health-care resources by 38%; Bacharier and colleagues8 
reported that intermittent montelukast therapy over 
12 months does not decrease wheeze severity in young 
children or need for oral corticosteroid therapy; and 
Valovirta and colleagues9 reported no beneﬁ cial eﬀ ect of 
a 12 month course of intermittent montelukast on 
wheeze attacks in young children. Reasons for these 
inconsistent results could be the substantial heterogeneity 
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in treatment eﬀ ect in young children with wheeze,10 and 
that the response to montelukast is limited to a subgroup 
of children.
Studies of adults with asthma suggest that hetero-
geneity in response to montelukast is partly determined 
by a polymorphism in the arachidonate 5-lipoxygenase 
(ALOX5) gene promoter. The ALOX5 gene encodes 
5-lipoxygenase—the rate-limiting enzyme in the 
cysteinyl leukotriene biosynthetic pathway.11,12 This 
polymorphism results from variable numbers of copies 
of the Sp1 binding motif GGGCGG, whereby ﬁ ve Sp1 
repeats are the major allele.13 Thus individuals are 
classiﬁ ed as either 5/5, or 5/x (in which x is not equal 
to 5), or x/x.14 To date, the ALOX5 promoter genotype 
grouping that best deﬁ nes montelukast responsiveness 
in adults is unclear. For example, Telleria and colleagues15 
reported increased montelukast responsiveness in adults 
with the 5/5 and the 5/x genotype (compared with x/x), 
whereas Lima and colleagues14 reported that both the 5/x 
and x/x genotypes were responsive to montelukast.
We did the Wheeze And Intermittent Treatment 
(WAIT) trial to assess the eﬃ  cacy of intermittent 
montelukast for wheeze in young children at increased 
risk of clinically severe episodes of wheeze.
Methods
Study design and participants
We did this multicentre, parallel-group, randomised, 
placebo-controlled trial between Oct 1, 2010, and Dec 20, 
2013, at 21 primary care sites and 41 secondary care sites 
in England and Scotland. Eligible children were aged 
between 10 months and 5 years and had had two or more 
previous episodes of wheeze, at least one of which was 
physician-conﬁ rmed, and at least one of which had 
happened in the preceding 3 months. We excluded 
children if they had a pre-existing respiratory 
vulnerability such as cystic ﬁ brosis, sickle-cell disease, 
severe developmental delay with feeding diﬃ  culty, 
history of neonatal chronic lung disease, or structural 
airways disease. Children were also excluded if they had 
been enrolled in a therapeutic trial in the previous 
3 months or were taking continuous oral montelukast at 
the time of enrolment. To represent the overall 
population of young children with wheeze, and in line 
with the population in our previous trials,4,16 we did not 
exclude children receiving continuous inhaled 
corticosteroid therapy. The study was approved by the 
UK National Health Service Multicenter Research Ethics 
Committee (reference number 09/H1102/110), by local 
institutional review boards, and by the UK Medicines 
and Healthcare Products Regulatory Agency 
(21313/0024/01-0001); the UK Medicines for Children 
Research Network supported the study. An independent 
data and safety monitoring committee not involved with 
patient enrolment reviewed adverse events. Written 
informed consent was obtained from the parent or 
guardian of each child enrolled in the study.
Randomisation and masking
Participants were allocated to either a 5/5 or 5/x+x/x 
ALOX5 promoter genotype stratum, then randomly 
assigned (1:1), via a permuted block schedule (size ten) 
developed by the manufacturer (Novalabs, Leicester, UK), 
to receive montelukast or placebo (appendix). Clinical 
investigators and parents were masked to treatment 
group and genotype strata. Placebo and montelukast 
were packaged as identical granules in identical sachets 
labelled with participant number only. Emergency code 
break was allowed in cases of a suspected severe adverse 
reaction when knowledge of patient allocation could have 
aﬀ ected clinical management of a study participant, in 
the case of a suspected unexpected severe adverse 
reaction, and in any other circumstance in which the 
principal investigator considered that an emergency code 
break was indicated.
Procedures
At enrolment, parents completed a structured 
question naire administered by research study 
personnel, which asked about previous wheeze, 
present treatment, and risk factors (appendix). Saliva 
from each child was collected with the Oragene OG-
250 collection kit in combination with the CS-1 saliva 
collection kit for young children (both manufactured 
by DNA Genotek, Ottawa, ON, Canada) and transferred 
to Queen Mary University of London (London, UK) for 
analysis. The simple sequence-length polymorphism 
in the promoter region of ALOX5 (rs59439148) was 
genotyped as described previously.17 Alleles were 
classiﬁ ed according to the number of simple repeats 
(appendix), and children were identiﬁ ed as belonging 
to either 5/5 or 5/x+x/x strata.
Parents were advised to commence the trial drug at the 
onset of each viral cold or wheezing episode over the 
12-month study period. Parents continued all other drugs 
prescribed by their managing clinician (including 
bronchodilators and inhaled corticosteroids), and 
completed a diary of symptoms, medicine use, adverse 
events, and medical attendance for each day the trial drug 
was given (appendix). Investigators asked parents by 
telephone survey about usage of trial drug, use of oral 
corticosteroid rescue therapy, and medical attendances at 
two-monthly intervals during the 12-month study period 
(appendix). Parents who could not be contacted received a 
maximum of two letters oﬀ ering continued involvement 
in the study. When parents could not be contacted for two 
successive phone calls, parent and child were regarded as 
withdrawn from the study. Medical attendances for 
wheeze were independently veriﬁ ed by study investigators 
by contact with the managing clinician.
Urine was obtained from asymptomatic children at 
baseline. Urine was transported on ice, and stored at 
–80°C within 1 h of collection. We analysed urinary 
leukotriene E4—the ﬁ nal urinary metabolite of cysteinyl 
leukotriene production—by high-performance liquid 
See Online for appendix
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chromatography–tandem mass spectrometry (ABI 
SCIEX 4000 QTRAP, Framingham, MA, USA), as 
previously described (appendix).18 Concentrations were 
expressed in proportion to urinary creatinine. We 
excluded samples with a urinary creatinine concentration 
of less than 0·1 mg/mL because correction is inaccurate 
in very dilute samples.
We monitored children for adverse events with a 
diary card report and telephone follow-up. Hospital 
admission for exacerbation of wheeze, acute lower-
respiratory-tract infection, acute febrile illness, febrile 
convulsion, gastroenteritis, and exacerbation of eczema 
were not classed as serious adverse events in the trial 
protocol.
Outcomes
Our primary outcome was the number of unscheduled 
medical attendances for wheezing episodes. Such 
attendances were deﬁ ned as those to a family doctor, an 
asthma nurse or similarly trained health-care 
professional, an accident and emergency department, 
hospital via accident and emergency (hospital 
admission), or any combination of these. Secondary 
outcomes were duration of hospital admission, number 
of wheeze episodes, duration of wheeze episodes, 
number of courses of oral steroids per year, proportion 
of children receiving oral corticosteroids, use of trial 
drug, time to ﬁ rst unscheduled medical attendance, and 
time to ﬁ rst unscheduled attendance by site of medical 
attendance. We did a prespeciﬁ ed subgroup analysis 
that assessed unscheduled medical attendances for 
wheeze episodes by ALOX5 promoter genotype strata 
(5/5 and 5/x+x/x). Other prespeciﬁ ed subgroups for 
analysis were multitrigger and episodic wheeze at 
baseline, use of either continuous inhaled corticosteroids 
or no inhaled corticosteroids at baseline, and the 
alternative genotype grouping of 5/5+5/x and x/x.
Statistical analysis
The trial was powered to detect a diﬀ erence in the 
number of unscheduled medical attendances for wheeze 
episodes between participants in the intervention and 
control groups, and to detect diﬀ erential responsiveness 
to montelukast in the 5/5 stratum compared with the 
5/x+x/x stratum, with the assumption that montelukast 
leads to a 60% reduction in attendances in the 5/x+x/x 
stratum, and a 20% reduction in the 5/5 stratum. With 
use of data from the UK General Practitioner Research 
Database, with courses of oral steroids as a proxy for 
unscheduled medical attendances for wheeze episodes, 
we estimated a mean of 0·76 [SD 1·22] such attendances 
per year. Because data follow an overdispersed Poisson 
distribution, we used Markov chain Monte Carlo 
simulation in WinBUGs (version 1.4) to estimate required 
sample sizes. 1050 children were needed to detect a 33% 
drop in unscheduled medical attendances for wheeze 
episodes, with a power of 90% at a signiﬁ cance level of 
5%, with a 6% loss to follow up. A 33% drop in attendances 
equates to an attack rate of 0·51 for the treatment group. 
The clinical signiﬁ cance of these changes is that roughly 
four children would need to be treated to prevent one 
unscheduled medical attendance. Because a sample size 
of 1200 provides just more than 80% power at the 5% 
signiﬁ cance level to detect an interaction between 
treatment and ALOX5 genotype, 1300 children needed to 
be recruited, assuming a 6% dropout. Interim safety 
analyses were done at 6-monthly intervals. Eﬃ  cacy 
analyses were done at the end of the trial.
For each child, we analysed unscheduled medical 
attendances for wheeze episodes and episodes of viral 
cold with a Poisson regression model. For each episode 
of wheeze and viral cold, duration of hospital admission, 
For more on WinBUGS see 
http://www.mrc-bsu.cam.ac.uk/
software/bugs/
90 discontinued follow-up
14 ineligible
2 had adverse events
5 had poor adherence
1 had perceived 
ineﬃcacy*
51 were unable to be 
located
17 other
1883 children screened 
for eligibility
1358 randomised
525 had no consent 
12 excluded
Parents of 11 children refused
permission to use data
No data collected for 1 child
669 assigned to montelukast 
group
416 in 5/5 stratum
253 in 5/x + x/x stratum
677 assigned to placebo 
group
426 in 5/5 stratum
251 in 5/x + x/x stratum
49 discontinued 
intervention
13 ineligible
4 had adverse events
1 had deterioration of 
pre-existing disorder
5 had poor adherence
9 had perceived 
ineﬃcacy*
5 could not be located
12 other
17 had no primary outcome data
652 included in analysis†
102 discontinued follow-up
13 ineligible
6 had adverse events
2 had poor adherence
8 had perceived 
ineﬃcacy*
36 were unable to be 
located
37 other
52 discontinued 
intervention
18 ineligible
3 had adverse events
1 had deterioration of 
pre-existing disorder
1 had poor adherence
9 had perceived 
ineﬃcacy*
2 could not be located
18 other
21 had no primary outcome data
656 included in analysis†
Figure 1: Trial proﬁ le 
*Perceived ineﬃ  cacy is on the side of patient. †Data for the primary outcome 
were obtained from children whose parents responded to at least one follow-up 
phone call.
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and number of symptom days were also analysed with 
Poisson regression models. We included follow-up time 
for each child as an exposure variable and a random 
eﬀ ect ﬁ tted for each child to account for overdispersion 
or when episode was the unit of analysis. Follow-up time 
was based on time from randomisation until either the 
12 month end of trial date or date of last phone call.
For unscheduled medical attendances for wheeze 
episodes, we assessed the diﬀ erential eﬀ ect of treatment 
in predeﬁ ned subgroups by inclusion of an interaction 
term. Proportions of patients who had any unscheduled 
medical attendance, or those receiving oral corticosteroid 
rescue therapy, were analysed with logistic regression. 
We analysed time to ﬁ rst unscheduled medical 
attendance with Cox regression models. All models were 
ﬁ tted on the available case population with modiﬁ ed 
intention-to-treat principles and included ﬁ xed eﬀ ects 
for stratiﬁ cation factor and treatment. We did a per-
protocol analysis that excluded any children randomised 
not according to schedule and that corrected for those 
randomised under the incorrect stratum. Parents who 
withdrew their children from the study and provided 
permission to use their data were included in the analysis 
to the point of withdrawal. Parents who withdrew their 
children and did not provide permission for their data to 
be used were excluded from the analysis. Because we 
anticipated few missing data, no imputation of missing 
data was done. All analyses were two-sided with a 5% 
signiﬁ cance level. Results are presented as incidence rate 
ratios (IRRs), odds ratios (ORs), or hazard ratios (HRs) as 
appropriate, with corresponding 95% CIs. To assess the 
eﬀ ect of ALOX5 genotype on urinary leukotriene E4, data 
were ﬁ rst log10 transformed to normalise distribution. 
Groups were compared with either ANOVA and 
Dunnett’s multiple comparisons test, or with t test using 
GraphPad Prism version 6.00 for Windows (GraphPad 
Software, La Jolla, CA, USA). Analyses were done with 
STATA Statistical Software: release 12.1. This trial is 
registered with ClinicalTrials.gov, number NCT01142505.
Role of funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all raw 
data and the corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Parents of 1366 children 
provided consent to enter the study, of whom eight 
withdrew children before randomisation. The remaining 
1358 children were randomly assigned to receive 
montelukast (n=669) or placebo (n=677; ﬁ gure 1). Data 
for the primary outcome were obtained from 1308 (96%) 
children whose parents responded to at least one 
follow-up phone call (ﬁ gure 1). Baseline demographic 
characteristics were similar between treatment groups. 
The per-protocol analysis included 1297 children. 
11 children were excluded who had been incorrectly 
randomised and the strata was corrected for two children 
Montelukast group (n=669) Placebo group (n=677)
5/5 5/x+x/x Total 5/5 5/x+x/x Total
n (%) 416 (62%) 253 (38%) 669 (100%) 426 (63%) 251 (37%) 677 (100%)
Height (cm) 90·0 (10·3) 89·8 (10·5) 89·9 (10·4) 89·9 (10·5) 91·8 (11·7) 90·6 (11·0)
Weight (kg) 14·0 (3·0) 13·9 (3·7) 14·0 (3·3) 14·0 (3·3) 14·6 (3·8) 14·2 (3·5)
Age (years) 2·6 (1·1) 2·5 (1·1) 2·6 (1·1) 2·6 (1·1) 2·8 (1·2) 2·7 (1·1)
Male sex 262 (63%) 164 (65%) 426 (64%) 276 (65%) 161 (64%) 437 (65%)
Ethnic origin
White 335 (81%) 179 (71%) 514 (77%) 338 (79%) 174 (69%) 512 (76%)
Black 5 (1%) 14 (6%) 19 (3%) 4 (1%) 14 (6%) 18 (3%)
Asian 55 (13%) 37 (15%) 92 (14%) 58 (14%) 46 (18%) 104 (15%)
Other 21 (5%) 23 (9%) 44 (7%) 26 (6%) 17 (7%) 43 (6%)
Preterm birth 
(<37 weeks)
58 (14%) 40 (16%) 98 (14%) 56 (13%) 42 (17%) 98 (15%)
Birthweight 
(<2500g)
51 (12%) 28 (11%) 79 (12%) 42 (10%) 28 (11%) 70 (10%)
Food allergy 64 (15%) 44 (18%) 108 (16%) 64 (15%) 47 (19%) 111 (17%)
Drug allergy 26 (6%) 12 (5%) 38 (6%) 23 (6%) 19 (8%) 42 (6%)
Itchy rash 
(>6 months, ever)*
98 (23%) 64 (25%) 162 (24%) 104 (25%) 60 (24%) 164 (25%)
Eczema (ever)† 207 (49%) 121 (48%) 328 (48%) 215 (52%) 134 (53%) 349 (52%)
History of asthma 
in mother
156 (37%) 95 (38%) 251 (37%) 141 (34%) 89 (35%) 230 (34%)
History of asthma 
in father
126 (30%) 73 (29%) 199 (29%) 126 (30%) 81 (32%) 207 (31%)
Age at ﬁ rst wheeze 
(months)
12·4 (9·8) 13·5 (10·5) 12·8 (10·1) 12·4 (10·4) 13·6 (11·5) 12·9 (10·8)
Children with 
episodic viral 
wheeze
296 (71%) 181 (72%) 477 (71%) 295 (69%) 191 (76%) 486 (72%)
Children with 
multitrigger 
wheeze
120 (29%) 72 (28%) 192 (29%) 131 (31%) 60 (24%) 191 (28%)
Interval between 
onset of URTI and 
wheezing (h)‡
31·6 (27·4) 28·8 (25·2) 30·5 (26·6) 27·3 (23·4) 28·2 (26·0) 27·7 (24·4)
Children with 
more than one 
hospital admission 
for wheeze in the 
past year
363 (87%) 216 (85%) 579 (87%) 351 (82%) 203 (81%) 554 (82%)
Courses of oral 
corticosteroids in 
past year
2·0 (1·9) 1·8 (1·8) 1·9 (1·8) 1·9 (1·9) 1·8 (2·0) 1·9 (2·0)
USMA in previous 
year
5·5 (4·3) 5·4 (4·1) 5·4 (4·2) 5·7 (5·3) 5·6 (4·6) 5·6 (5·1)
Continuous 
inhaled 
corticosteroids
118 (28%) 66 (26%) 184 (28%) 144 (34%) 69 (27%) 213 (31%)
Data are mean (SD) or n (%), unless otherwise indicated. USMA=unscheduled medial attendance for wheeze. 
URTI=upper-respiratory-tract infection. *A question to parents from the International Study of Asthma and Allergies in 
Childhood questionnaire was used to identify symptoms suggestive of eczema. †Eczema from birth was based on 
parental report to recruiting investigator at enrolment. ‡Based on parental report of the usual interval between URTI 
and onset of wheezing. 
Table 1: Baseline characteristics 
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who were randomised with incorrect strata. There were 
no major diﬀ erences in baseline variables between 
children in the placebo and montelukast groups or 
between the two genetic strata (table 1). The dominant 
allele was ﬁ ve repeats (table 1), and consistent with 
previous reports,14,19 black children had a greater frequency 
of x alleles (75% vs 31% in white children; appendix).
Overall, we recorded 1310 unscheduled medical 
attendances for wheeze episodes in the montelukast 
group and 1480 such attendances in the placebo group. 
There was no diﬀ erence in mean medical attendances 
between the montelukast and placebo groups (table 2). 
These conclusions remained the same when the analysis 
was repeated in the per-protocol population. Compared 
with placebo, children in the 5/5 ALOX5 promoter 
stratum had reductions in unscheduled medical 
attendances for wheeze episodes (table 2). By contrast, 
there was no diﬀ erence in medical attendances between 
children in the montelukast and placebo groups in the 
5/x+x/x stratum (table 2).
No diﬀ erence was recorded between the montelukast 
and placebo groups for the number of children who had 
at least one unscheduled medical attendance for wheeze 
episodes, the number of wheeze episodes, or the duration 
of wheeze episodes (table 3). There was also no diﬀ erence 
between treatment groups for time to ﬁ rst unscheduled 
medical attendance (table 3). Time to ﬁ rst hospital 
admission was increased in the montelukast group 
(p=0·04; appendix). There was no diﬀ erence between the 
montelukast and placebo groups for attendances to 
accident and emergency (appendix). Mean number of 
courses of rescue oral corticosteroids were lower in 
children given montelukast than in those given placebo 
(table 3), but there was no diﬀ erence in the proportion of 
children receiving at least one course of rescue oral 
corticosteroids (appendix). In the montelukast group, 
study drugs were reported to be eﬀ ective by 323 (56%) of 
579 parents at the 12-month timepoint; 58 (10%) parents 
were unsure, and 69 (12%) did not respond. In the 
placebo group, study drugs were reported to be eﬀ ective 
by 299 (52%) of 575 parents; 58 (10%) parents were 
unsure, and 78 (14%) did not respond.
There was no signiﬁ cant interaction for pattern of 
wheeze at baseline (multitrigger vs episodic wheeze), use 
of regular inhaled corticosteroids, or a diﬀ erent grouping 
of ALOX5 promoter genotype 5/5+5/x and x/x  (appendix).
Of the 940 adverse events reported in the study, 657 (70%) 
were classiﬁ ed as deﬁ nitely not related to study drug, 179 
(19%) as probably not related, 93 (10%) as possibly related, 
11 (1%) as probably related, and no adverse event was 
deﬁ nitely related (appendix). We recorded one serious 
adverse event, which was a skin reaction in a child allocated 
to placebo (appendix). The distribution of adverse events 
was similar between groups (table 4).
Urine was obtained from 975 asymptomatic children 
at recruitment. We excluded children with concentrations 
of urinary creatinine of less than 0·1 mg/mL (n=26), 
resulting in analysis of 597 (63%) children with the 
5/5 genotype, 312 (33%) with the 5/x genotype, and 
40 (4%) with the x/x genotype. Urinary leukotriene E4 
(log10 transformed) was higher in children with the 
x/x genotype than in those with the 5/5 genotype 
(ﬁ gure 2). There was no signiﬁ cant diﬀ erence in urinary 
leukotriene E4 between the 5/5 and 5/x genotypes, or the 
5/5 and 5/x+x/x genotypes (data not shown).
Discussion
Our ﬁ ndings show that intermittent montelukast 
treatment, although not associated with side-eﬀ ects, did 
not reduce unscheduled medical attendances for wheeze 
episodes in children younger than 5 years. These results 
are in line with those of Bacharier and colleagues,8 who 
reported that intermittent montelukast in young children 
with wheeze does not increase the proportion of episode-
free days or decrease the proportion of children who need 
urgent medical care, and with those of Valovirta and 
colleagues9 who noted that intermittent montelukast does 
Montelukast 
group 
(n=652)
Placebo 
group 
(n=656)
Adjusted incidence 
rate ratio (95% CI)
p value pinteracttion
Primary analysis
USMA episodes 2·0 (2·6) 2·3 (2·7)  0·88 (0·77–1·01) 0·06 ..
Subgroup analysis 
USMA in 5/5 stratum 2·0 (2·7) 2·4 (3·0) 0·80 (0·68–0·95) 0·01 ..
USMA in 5/x+x/x stratum 2·0 (2·5) 2·0 (2·3)  1·03 (0·83–1·29) 0·79 0·08
Data are mean (SD), unless otherwise indicated. We obtained primary outcome data from the phone call that took 
place every 2 months. USMA=unscheduled medial attendance for wheeze.
Table 2: Treatment response in the primary analysis, and by 5/5 and 5/x+x/x strata
Montelukast 
group (n=652)
Placebo group 
(n=656)
Point estimate 
(95% CI)
p value
Children with one or more 
USMA
426 (65%) 456 (70%) OR 0·83 (0·66–1·04) 0·10
Time to ﬁ rst USMA (days)* 147 (50–365) 130 (38–)†  HR 0·89 (0·78–1·02) 0·09
Need for rescue oral 
corticosteroids (courses per 
child)‡
0·26 (0·7) 0·33 (0·9)  IRR 0·75 (0·58–0·98) 0·03
Wheeze episodes‡ 2·7 (2·9) 2·6 (3·0) IRR 1·02 (0·91–1·16) 0·68
Duration of wheeze 
episodes (days)
5·2 (4·0) 5·4 (3·8) IRR 0·97 (0·89–1·06) 0·53
Duration of hospital 
admission (days per 
admission)
1·8 (1·3) 1·7 (1·1) IRR 1·05 (0·94–1·18) 0·40
Symptomatic days per 
wheeze episode
4·9 (3·5) 4·8 (3·8) IRR 0·96 (0·88–1·05) 0·36
Data are n (%), median (IQR), or mean (SD), unless otherwise indicated. USMA=unscheduled medical attendance for 
wheeze episodes. OR=odds ratio. HR=hazard ratio. IRR=incidence rate ratio. *Seven participants were missing dates for 
USMA and seven participants had their ﬁ rst medical attendance on the day of randomisation and were hence excluded. 
†The 75th percentile could not be calculated for this IQR  because more than 25% of children never had a USMA. 
‡Analysis included all children. 446 children had no diary data and these participants were considered to have no 
wheeze and cold episodes. When the analysis was repeated with these patients treated as missing, there was no 
diﬀ erence in the IRR between treatment and placebo. 
Table 3: Secondary outcomes 
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not reduce the number of wheeze episodes culminating in 
need for unscheduled medical care or rescue oral 
corticosteroids. Use of oral steroid rescue therapy in 
our study was much lower than unscheduled medical 
attendances for wheeze episodes. We postulate that this 
ﬁ nding shows a change in UK prescribing practice in view 
of studies reporting oral steroids to be ineﬀ ective in acute 
wheeze in young children.4,16 We recorded a reduction in 
use of oral corticosteroid in children given montelukast, 
but in the context of present UK prescribing practice, the 
clinical signiﬁ cance of a change in this indirect marker of 
wheeze severity is unclear. Our results diﬀ er to those from 
Robertson and colleagues7 who, in a subgroup analysis, 
showed that intermittent montelukast is eﬀ ective in 
reducing unscheduled use of health-care resources in 
children aged 2–5 years. To resolve these contradictory 
ﬁ ndings, we did a meta-analysis of trials of intermittent 
montelukast for unscheduled medical attendances for 
wheeze episodes (appendix). Findings of this meta-analysis 
showed no beneﬁ t of a 12 month period of intermittent 
montelukast therapy on unscheduled medical attendances 
for wheeze (appendix). This outcome suggests that 
intermittent montelukast is not an eﬀ ective treatment 
strategy for treatment of young children with a history of 
two or more episodes of wheeze (panel).
In the present study, the 95% CI of the IRR for 
unscheduled medical attendances for wheeze excluded a 
33% reduction in such attendances. However, the fewer 
unscheduled medical attendances in the montelukast 
group, albeit non-signiﬁ cant, suggests heterogeneity of 
treatment response—a characteristic of previous studies 
in young children with wheeze. For example, response to 
continuous inhaled corticosteroids is most favourable in 
the subgroup of white males with an unscheduled medical 
attendance for wheeze in the previous 12 months and 
aeroallergen sensitisation.21 Furthermore, in Bacharier 
and colleagues’ study,8 intermittent montelukast, despite 
having no overall beneﬁ t, reduced the area under the 
curve for wheezing score in children with a positive 
asthma predictive index, deﬁ ned as four or more wheezing 
episodes with at least one diagnosed by a doctor, and one 
or more major criteria of parental asthma, doctor-
diagnosed dermatitis, allergic sensitisation to one or more 
aeroallergen, or at least two minor criteria of allergic 
sensitisation to milk, egg, or peanuts; wheeze unrelated to 
colds; and blood eosinophils greater than 4%.22 We did not 
stratify by asthma predictive index because Meyer and 
colleagues22 reported that no clinical variable predicts 
response to continuous montelukast in wheeze in young 
children, and blood sampling, in our experience, greatly 
reduces the willingness of parents to enter their infants 
into a therapeutic trial. Furthermore, use of parental-
reported diagnosis for disorders such as eczema 
overestimates physician-diagnosed disease.23 As such, we 
cannot exclude montelukast responsiveness in children 
with a positive asthma predictive index. However, our 
prespeciﬁ ed subgroup analyses showed that neither the 
pattern of wheeze nor use of inhaled corticosteroids was 
associated with montelukast response, although our study 
was not powered for these interactions.
In adults with asthma, heterogeneity in response to 
montelukast is associated with a polymorphism in the 
ALOX5 promoter.14,15 In line with these studies in adults, 
we recorded a 20% reduction in unscheduled medical 
attendances for wheeze in children in the montelukast 
group with the 5/5 ALOX5 promoter genotype, and no 
eﬀ ect of intermittent montelukast in those with the 
Montelukast (n=669) Placebo (n=677)
Number of events* 397 543
Participants with events 197 (29%) 235 (35%)
Intensity 
Mild 314 (79%) 426 (78%)
Moderate 77 (19%) 108 (20%)
Severe 6 (2%) 9 (2%)
Minor injury 27 (7%) 22 (4%)
Gastrointestinal 86 (22%) 122 (22%)
Upper-respiratory-tract 
infection
73 (18%) 103 (19%)
CNS 25 (6%) 46 (8%)
Minor infection 87 (22%) 107 (20%)
Allergy 16 (4%) 20 (4%)
Cutaneous 32 (8%) 54 (10%)
Respiratory 34 (9%) 54 (10%)
Haematological 5 (1%) 7 (1%)
Genitourinary 10 (3%) 6 (1%)
Major injury 2 (1%) 1 (<1%)
Musculoskeletal 0 1 (<1%)
Data are n (%), unless otherwise indicated. See appendix for full details of adverse 
events. *No adverse events were deﬁ nitely treatment-related
Table 4: Non-serious adverse events
Figure 2: Dot plot of urinary LTE4 by variable numbers of copies of the Sp1-
binding motif (either 5/5, 5/x, or x/x, in which x does not equal 5) in the 
ALOX5 promoter region 
11 datapoints were outside the axis and are not shown for convenience. 
Horizontal bars within plots represent mean. LTE4=leukotriene E4. 
ALOX5=arachidonate 5-lipoxygenase. 
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5/x+x/x genotype. The montelukast-responsive genotype 
(5/5) in the present study is, however, diﬀ erent from our 
a-priori hypothesis, as suggested by the 5/x+x/x grouping 
from Lima and colleagues’ study.14 But other studies in 
adults report montelukast responsiveness of the 
5/5 genotype. For example, Telleria and colleagues15 
reported decreased asthma exacerbations and improved 
lung function in adults with the 5/5 genotype who were 
given montelukast, and Drazen and colleagues24 showed 
that ABT-761 (a 5-lipoxygenase inhibitor) improved lung 
function in adults with the 5/5 genotype, but not in those 
with the x/x genotype. We sought support for a diﬀ erential 
response to montelukast between genotypes by 
measurement of urinary leukotriene E4.25 In the only 
study in children to date, Mougey and colleagues19 
measured urinary leukotriene E4 and identiﬁ ed 
ALOX5 polymorphism status in 270 6–17-year-old 
children with poorly controlled asthma enrolled into a 
6 month (negative) trial of acid-reﬂ ux treatment. Children 
with the x/x genotype (73% of whom were receiving 
montelukast) had signiﬁ cantly higher concentrations of 
urinary leukotriene E4, worse forced expiratory volume in 
1 s, and a trend for poorer asthma control than those with 
the 5/5+5/x genotypes.19 Similarly, we recorded increased 
urinary leukotriene E4 in children with the x/x genotype 
compared with those with the 5/5 or 5/5+5/x genotypes. 
These data provide support for a diﬀ erential response to 
montelukast between 5/5 and x/x genotypes; however, 
they do not explain a diﬀ erential response between the 
5/x and 5/5 genotypes. We postulate that diﬀ erences in 
production of cysteinyl leukotriene between 5/x and 
5/5 genotypes might be shown during children’s wheeze 
episodes when cysteinyl leukotriene production is 
increased.26
These data do not support the routine use of 
intermittent montelukast for wheeze in children aged 
10 months to 5 years. Further stratiﬁ ed trials should be 
done to conﬁ rm the presence of a responsive subgroup.
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Panel: Research in Context
Systematic review
We did a search between June 30, and July 10, 2014, using the 
research strategy reported by Ducharme and colleagues.20 We 
searched Embase, Scopus, Medline, and the Cochrane Airways 
Group trials register for additional studies between Jan 1, and 
July 30, 2014, with search terms “wheez* or asthm*”, 
“preschool* or preschool**”, “randomised or randomized or 
randomly or trial”, “leukotriene* or anti-leukotriene or 
antileukotriene or montelukast”. We also included 
“viralwheeze or viral-wheeze”, “young children and infant”, 
“intermittent, pre-emptive, and preemptive”. Our search 
retrieved no additional trials to those previously identiﬁ ed.7–9
Interpretation
Whether intermittent treatment with montelukast is eﬀ ective 
for treatment of wheeze in children aged 10 months to 5 years 
is unclear: one randomised trial7 showed that intermittent 
montelukast is eﬀ ective for wheeze in that population, 
whereas two other trials8,9 reported no beneﬁ t. We therefore 
sought to establish the eﬃ  cacy of intermittent montelukast in 
young children with wheeze. Because young children with 
wheeze exhibit marked heterogeneity in response to 
montelukast, and in adults, copy numbers of the GGGCGG Sp1 
binding motif in the arachidonate 5-lipoxygenase (ALOX5) 
gene promoter (either 5/5, 5/x, or x/x, in which x does not 
equal 5) are associated with heterogeneity in montelukast 
response,14,15 we stratiﬁ ed the trial by 5/5 and 5/x+x/x 
genotypes. Our ﬁ ndings show that intermittent montelukast 
is no better than placebo for reducing the need for 
unscheduled medical attention in young children with a 
history of clinically severe wheeze. Evidence suggested that 
children with the 5/5 genotype might be responsive to 
intermittent montelukast treatment. For clinicians, these data 
suggest that intermittent montelukast should not be routinely 
used to treat wheeze in young children. Further data from 
stratiﬁ ed trials are needed before treatment is targeted to a 
responsive subgroup.
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